HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 11-30-2006, 10:56 AM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
success of gamma knife for brain mets greater if 3 or less mets

Cancer. 2006 Nov 28; [Epub ahead of print] Links
Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases.

Diluna ML,
King JT Jr,
Knisely JP,
Chiang VL.
Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut.
BACKGROUND.: Little is understood about the factors that influence survival in patients who undergo gamma-knife stereotactic radiosurgery (SRS) for brain metastases. METHODS.: Demographic, disease, treatment, and survival data on 334 patients with intracranial metastases who underwent initial SRS from 1998 to 2004 were abstracted from treatment records and from the Connecticut Tumor Registry. Multivariate survival analysis was used to identify factors that independently affected survival. RESULTS.: The median age of the patient population was 57.3 years. The median number of lesions treated in a single session was 2 (range, 1-36 lesions treated). The most common tumor histologies were nonsmall cell lung carcinoma (36%), breast cancer (16%), and melanoma (16%). Three hundred patients (90%) had confirmed deaths; the median survival after SRS was 8.1 months. Survival was significantly better in patients who had from 1 to 3 metastases (median, 8.5 months) compared with patients who had >/=4 metastases (median, 6.3 months; hazard ratio [HR], 0.65; P = .003). In the subgroup of patients who had from 1 to 3 metastases, systemic control (HR, 0.49; P < .001), breast cancer (HR, 0.57; P = .003), and total tumor volume < 5 cc (HR, 0.65; P = .002) were associated independently with increased survival, and esophageal cancer (HR, 2.36; P = .042) was associated with decreased survival. In the subgroup of patients who had >/=4 metastases, only age <45 years was associated independently with increased survival (HR, 0.39; P = .006); and melanoma (HR, 2.32; P = .008) and the receipt chemotherapy (HR, 2.59; P = .077) were associated with decreased survival. Sex, race, metastases location, whole-brain radiation, and cranial surgery had no independent associations with altered survival. CONCLUSIONS.: The data from this study suggested that different factors affected survival in patients who had from 1 to 3 metastases and patients who had >/=4 metastases. Further research into this area may clarify causes for this discrepancy and improve prognostication. Cancer 2007. (c) 2006 American Cancer Society.
PMID: 17133440 [PubMed - as supplied by publisher]
Lani is offline   Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 12:34 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter